Study identifier:D3690C00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia
schizophrenia
Phase 2
No
AZD3480
All
445
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and tolerability of AZD3480 and to define the optimal dose(s) to be used in future trials.
Location
Location
BURLINGTON, ON, Canada
Location
CALGARY, AB, Canada
Location
HALIFAX, NS, Canada
Location
MISSISSAUGA, ON, Canada
Location
MONTREAL, QC, Canada
Location
ORLEANS, ON, Canada
Location
PENTICTON, BC, Canada
Location
RED DEER, AB, Canada
Arms | Assigned Interventions |
---|---|
Placebo Comparator: 1 Placebo | Drug: AZD3480 oral capsule |
Experimental: 2 AZD3480 oral | Drug: AZD3480 oral capsule |
Experimental: 3 AZD3480 oral dose | Drug: AZD3480 oral capsule |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.